Crisafulli, Salvatore
Fontana, Andrea
L’Abbate, Luca
Ientile, Valentina
Gianfrilli, Daniele
Cozzolino, Alessia
De Martino, Maria Cristina
Ragonese, Marta
Sultana, Janet
Barone-Adesi, Francesco
Trifirò, Gianluca
Funding for this research was provided by:
Ministero dell'Università e della Ricerca (2017N8CK4K)
Article History
Received: 20 May 2022
Accepted: 12 September 2022
First Online: 23 September 2022
Competing interests
: G.T. has served in the last three years on advisory boards/seminars funded by SANOFI, Eli Lilly, AstraZeneca, Abbvie, Servier, Mylan, Gilead, Amgen; he was the scientific director of a Master program on pharmacovigilance, pharmacoepidemiology and real-world evidence which has received non-conditional grant from various pharmaceutical companies; he coordinated a pharmacoepidemiology team at the University of Messina until October 2020, which has received funding for conducting observational studies from various pharmaceutical companies (Boehringer Ingelheim, Daichii Sankyo, PTC Pharmaceuticals). He is also scientific coordinator of the academic spin-off "INSPIRE srl" which has received funding for conducting observational studies from contract research organizations (RTI Health Solutions, Pharmo Institute N.V.). None of these listed activities are related to the topic of the manuscript. The other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.